The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“N...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, In...
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023....
MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc...
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Hal...
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET...
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500...